SCHEMBL145362

SCHEMBL145362

COC(=O)c1cc(-c2ccc(OC)cc2)nc2c1[nH]c1cc(OCc3ccccc3)ccc12

nearest known ligand 0.66

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 3/20 0.66
DHODH Q02127 3/20 0.49
PLA2G2A P14555 7/20 0.48
MAOA P21397 1/20 0.46
KDM4E B2RXH2 2/20 0.46
ALDH1A1 P00352 2/20 0.46
GABRA1 P14867 1/20 0.46
GABRG2 P18507 1/20 0.46
GABRB3 P28472 1/20 0.46
GABRA3 P34903 1/20 0.46
GABRA2 P47869 1/20 0.46
FLT3 P36888 1/20 0.45
MEN1 O00255 1/20 0.45
MAPK1 P28482 1/20 0.45
HTT P42858 1/20 0.45
KMT2A Q03164 1/20 0.45
HSD17B10 Q99714 1/20 0.45
TACR3 P29371 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL141099 0.95 JAK2 (0.58) JAK2DHODHPLA2G2AMAOAKDM4E
SCHEMBL142347 0.93 JAK2 (0.56) JAK2DHODHPLA2G2AMAOAGABRA1
SCHEMBL142210 0.91 JAK2 (0.63) JAK2DHODHMAOAGABRA1GABRG2
SCHEMBL141522 0.87 JAK2 (0.80) JAK2PLA2G2AKDM4EALDH1A1HSD17B10
SCHEMBL140965 0.86 JAK2 (0.69) JAK2PLA2G2AMAOAKDM4EALDH1A1
SCHEMBL143133 0.86 JAK2 (0.49) JAK2DHODHMAOAKDM4EALDH1A1
SCHEMBL145515 0.85 MAOA (0.49) JAK2DHODHMAOAKDM4EALDH1A1
SCHEMBL143789 0.84 JAK2 (0.52) JAK2DHODHMAOAKDM4EALDH1A1
SCHEMBL142655 0.80 JAK2 (0.78) JAK2PLA2G2AKDM4EALDH1A1
SCHEMBL143862 0.80 JAK2 (1.00) JAK2PLA2G2AKDM4EALDH1A1TACR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
EP-2370407-B1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-06-18 EP disclosed
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
EP-2370407-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2011-10-05 EP disclosed
WO-2010080474-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS JAK2, JAK1, JAK3 JAK2 1/4885DHODH 3348/4885PLA2G2A 4509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.